Matinas Biopharma Appoints Evelyn D’An as Director and Audit Committee Chair

BEDMINSTER, N.J. (February 7, 2025) – Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) announced today that Evelyn D’An has been appointed to its Board of Directors as an independent director and Chair of the Audit Committee, effective February 5, 2025. The appointment of Ms. D’An was made by the Board of Directors of Matinas BioPharma […]

Leave a Reply

Your email address will not be published.

Previous post Promising Construction Stocks To Follow Now – February 07th
Next post Eton Pharmaceuticals Receives FDA Extension for NDA for ET-400On February 6, 2025, Eton Pharmaceuticals, Inc. announced through a press release that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) g